Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serlopitant - Menlo Therapeutics

Drug Profile

Serlopitant - Menlo Therapeutics

Alternative Names: JTS 661; MK-0594; VPD-737

Latest Information Update: 07 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Epidermolysis Bullosa Research Partnership; Japan Tobacco; Menlo Therapeutics; Merck & Co; Stanford University; Torii Pharmaceutical
  • Class Antipruritics; Antitussives; Cyclopentanes; Isoindoles; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pruritus
  • Discontinued Alcoholism; Cough; Overactive bladder

Most Recent Events

  • 31 Oct 2019 Menlo Therapeutics plans a phase-III trial for Pruritus (associated with Psoriasis) in 2020
  • 29 Oct 2019 Menlo Therapeutics intends to file NDA for Pruritus (associated with Prurigo nodularis) in second half of 2020
  • 29 Oct 2019 Menlo Therapeutics completes enrolment in its phase III trial for Pruritus (associated with Prurigo nodularis) in Austria, Poland and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top